Patents by Inventor Lingling Weng

Lingling Weng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydrogen sulfide donor in organic salt form and preparation method therefor
    Patent number: 11124475
    Abstract: A hydrogen sulfide donor in an organic salt form and a preparation method thereof. The hydrogen sulfide donor exists as a salt formed by organic compounds with an alkaline motif and hydrogen sulfide with weak acidity. The hydrogen sulfide donor features with a simple structure, and an easy preparation method. Moreover, hydrogen sulfide donors in different forms can be prepared according to research and development needs. After the hydrogen sulfide donor enters an organism, the process of in vivo dissociation and hydrogen sulfide supply is simple, rapid, and effective, and there is no requirement for enzyme or any other complicated condition, and thus, the hydrogen sulfide donor has a great application prospect and value.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 21, 2021
    Assignee: CHENGDU KAOENSI SCIENCE AND TECHNOLOGY CO., LTD.
    Inventors: Hu Zheng, Lingling Weng
  • HYDROGEN SULFIDE DONOR IN ORGANIC SALT FORM AND PREPARATION METHOD THEREFOR
    Publication number: 20200199067
    Abstract: A hydrogen sulfide donor in an organic salt form and a preparation method thereof. The hydrogen sulfide donor exists as a salt formed by organic compounds with an alkaline motif and hydrogen sulfide with weak acidity. The hydrogen sulfide donor features with a simple structure, and an easy preparation method. Moreover, hydrogen sulfide donors in different forms can be prepared according to research and development needs. After the hydrogen sulfide donor enters an organism, the process of in vivo dissociation and hydrogen sulfide supply is simple, rapid, and effective, and there is no requirement for enzyme or any other complicated condition, and thus, the hydrogen sulfide donor has a great application prospect and value.
    Type: Application
    Filed: March 15, 2018
    Publication date: June 25, 2020
    Inventors: Hu ZHENG, Lingling WENG
  • Bone resorption inhibition/osteogenesis promotion compound
    Patent number: 6028207
    Abstract: A compound represented by the following formula (I):X--Y--Z (I)where Y is represented by the following formulae: ##STR1## X is a monovalent group of a tetracycline type compounds and Z is a monoent group of a steroid type compound such as estrogen.The compound can concentrate on the bone tissue and has bone resorption inhibition/ossification promotion functions.
    Type: Grant
    Filed: July 3, 1997
    Date of Patent: February 22, 2000
    Assignees: Iskra Industry Co., Ltd., Institute of Pharmacology, West China University of Medical Sciences
    Inventors: Hu Zheng, Lingling Weng
  • Bone resorption inhibition/osteogenesis promotion compound
    Patent number: 5760214
    Abstract: A compound represented by the following formula (I):X--Y--Z (I)?where Y is represented by the following formula (III): ##STR1## X is a monovalent group of a tetracycline type compound, and Z is a monovalent group of a steroid type compound such as estrogen!. The compound can concentrate on the bone tissue and has a bone resorption inhibition/ossification promotion functions.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: June 2, 1998
    Assignees: Iskra Industry Co., Ltd., Institute of Pharmacology, West China Univ. of Medical Sciences
    Inventors: Hu Zheng, Lingling Weng
  • Bone resorption inhibition/osteogenesis promotion pharmaceutical composition
    Patent number: 5698542
    Abstract: A pharmaceutical composition comprising a compound represented by the following formula (I):X--Y--Z (I)?where Y is represented by the following formula (III): ##STR1## X is a monovalent group of a tetracycline type compound, and Z is a monovalent group of asteroid type compound such as estrogen!.The compound can concentrate on the bone tissue and has a bone resorption inhibition/ossification promotion functions.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: December 16, 1997
    Assignees: Iskra Industry Co., Ltd., Institute of Pharmacology, West China Univ. of Medical Sciences
    Inventors: Hu Zheng, Lingling Weng